News ArchivesRead News
New research program tackles Parkinson’s disease
Tuesday December 19, 2006
December 14, 2006(University of Wisconsin System) - A new research collaboration at the University of Wisconsin-Madison aims to move promising new therapies for Parkinsons disease from primates to patients.
Based at the Wisconsin National Primate Research Center and named the Preclinical Parkinsons Disease Research Program, the collaboration became official in November. Joseph Kemnitz, professor of physiology and Primate Center director, is the programs executive director. Renowned Parkinsons disease expert Marina Emborg, senior scientist at the Primate Center and in the department of anatomy, is scientific director. "Our goal is to hasten discoveries that will lead to new therapies for Parkinsons disease, with an emphasis on cell and gene-based therapies," says Kemnitz.
Through the new program, the Primate Center is poised to become the countrys centralized resource for Parkinsons disease research using nonhuman primate models, especially macaques, Kemnitz says. Program collaborators and funding agencies that will help develop the necessary laboratory and animal resources at the Primate Center include WinCon, a biotechnology company in Nanning, Guangxi, China; researchers at the Beijing Institute of Geriatrics, and an anonymous foundation.
"Macaques are regarded by many as the most useful model for Parkinsons research," Kemnitz says. "These collaborators chose the Wisconsin National Primate Research Center because we have a well established infrastructure for conducting research using nonhuman primates, and UW-Madison has a broad range of expertise directly relevant to this program."
That expertise lies in the UW-Madisons renowned capabilities in brain imaging technology, stem cell biology and clinical biomanufacturing. Researchers from the Primate Center, Waisman Center, School of Medicine and Public Health, School of Pharmacy, and other campus entities are already developing promising Parkinsons therapies based on embryonic stem cell derivations, trophic (nutritive) factors, compounds called thiazolidenediones, deep brain stimulation and other treatment avenues.
"Were committed to finding a cure for Parkinsons disease," Emborg says.
Recent NewsJul 20 - Parkinson’s DREAM Challenge Uses Mobile Sensor Data to Monitor Health Based on Movement
Jul 19 - What Young-onset Parkinson’s Can Look Like
Jul 7 - Parkinson’s Patients Have a Higher Risk of Developing Melanoma — and Vice Versa, Study Finds
Jun 27 - The rogue protein behind Parkinson’s disease may also protect your gut
Jun 26 - Do Statins Increase Risk of Parkinson’s Disease? Some Researchers Think So
Jun 22 - A Confused Immune System Could Be Behind Parkinson's Disease
Jun 21 - Predicting cognitive deficits in people with Parkinson’s disease
Jun 20 - Gym offers classes in noncontact boxing for Parkinson’s patients
Jun 19 - Human Limitations Could Prevent Us From Advancing in Science. AI Could Help.
Jun 13 - Brain Cell Transplants Are Being Tested Once Again For Parkinson's
Jun 12 - Smell Test May Sniff Out Oncoming Parkinson's and Alzheimer's
Jun 8 - Smartphones Track Motor Function in Parkinson's Disease
Jun 8 - GKC Enrolls First Patient in Personal KinetiGraph Trial as Part of NPF’s Parkinson’s Outcomes Project
Jun 8 - Low-fat dairy intake may raise Parkinson's risk
Jun 6 - Patient Voices: Parkinson's Disease
Jun 1 - World-First Trials Have Been Launched to Treat Parkinson's And Blindness With Embryonic Stem Cells
Jun 1 - LIFE Shared This Remarkable Parkinson's Disease Story in 1959.
May 24 - Survival Rates Differ Widely in Parkinson's, MSA, Lewy Bodies
May 22 - Discovery may offer hope to Parkinson's disease patients
May 15 - Study offers answers on life expectancy for people with Parkinson's disease, Lewy body dementia